News + Filings Key Docs Ownership
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Inventiva S.A. (IVA)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/28/2023 |
6-K
| Quarterly results |
09/28/2023 |
6-K
| Quarterly results |
09/28/2023 |
6-K
| Quarterly results |
07/27/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Inventiva Reports Preliminary 2023 First-Half Financial Information 1 and Business update Daix , Long Island City , July 27, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, today reported certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update. Preliminary Financial Results As of June 30, 2023, the Company’s cash and cash equivalents amounted to €31.2 million, short-term deposits to 0.05 million 2 , and long-term deposit to €9.3 million 3 , compared to €86.7 million, €1.0 million a..." |
|
05/26/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/25/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/25/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/16/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/05/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/04/2023 |
6-K
| Quarterly results |
04/25/2023 |
6-K
| Quarterly results |
04/17/2023 |
6-K
| Quarterly results |
03/29/2023 |
6-K
| Quarterly results |
02/14/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Inventiva reports preliminary financial results for Full-Year 2022 1 Daix , Long Island City , February 14, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, today reported certain preliminary financial results as of and for the year ended December 31, 2022. Preliminary Financial Results 1 Cash and cash equivalents, short-term deposits, R&D Expenses, Net cash used in operating activities, Net cash generated from investing activities and Net cash generated from financing activities. As of December 31, 2022, the Company had €86.7 million of cash and cash equivalents and €1.0 million of sho..." |
|
01/26/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023 Daix , Long Island City , January 26, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ General Meeting. The Combined Shareholders' Meeting was held on January 25, 2023 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon , under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva. Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the ..." |
|
01/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/04/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/19/2022 |
6-K
| Quarterly results |
12/12/2022 |
6-K
| Quarterly results |
11/21/2022 |
6-K
| Quarterly results |
11/10/2022 |
6-K
| Quarterly results |
10/31/2022 |
6-K
| Quarterly results |
09/27/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
09/22/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
07/28/2022 |
6-K
| Quarterly results |
07/05/2022 |
6-K
| Quarterly results |
05/20/2022 |
6-K
| Quarterly results |
05/19/2022 |
6-K
| Quarterly results |
05/16/2022 |
6-K
| Quarterly results |
05/16/2022 |
6-K
| Quarterly results |
05/02/2022 |
6-K
| Quarterly results |
04/28/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Combined General Meeting of May 19, 2022 Availability of the preparatory documents Daix , Long Island City , April 28, 2022 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 19, 2022. Shareholders are invited to participate in the annual Combined General Meeting that will be held on May 19, 2022 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon . The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined Genera...",
"Statement of total voting rights and shares forming the company’ s share capital as of April 11, 2022" |
|
04/25/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
|
|
|